Navigation Links
PhRMA Launches Campaign to Raise Awareness of Success of Medicare Prescription Drug Benefit

WASHINGTON, June 10 /PRNewswire-USNewswire/ -- With the debate over comprehensive healthcare reform now in full swing, the Pharmaceutical Research and Manufacturers of America is launching a new national broadcast advertising campaign touting the importance and success of free-market initiatives such as the Medicare prescription drug benefit (Part D).

Medicare Part D continues to provide unprecedented coverage and choice for seniors and disabled Americans, according to national surveys. And most importantly, seniors are saving money on their medicines through the program, particularly those who need it the most. According to the Centers for Medicare and Medicaid Services (CMS), the average value of the Part D benefit, premium subsidy, and cost-sharing subsidy in 2009 will be $1,200 for the average beneficiary, and about $3,900 for low-income.

In fact, in 2009, approximately 97 percent of beneficiaries in a stand-alone plan have access to a monthly premium less or equal to the premium they paid in 2008, according to CMS. And every state offers a Medicare prescription drug plan with a premium of $23 or less.

A recent Medicare Today survey, cited in the commercial, shows overall satisfaction has grown from 78 percent at the start of the program in 2006, to 84 percent in 2009. In addition, the new commercial also pushes for comprehensive healthcare reform.

"There is a success story out there in healthcare, and we want people to know about it. Since its inception, the Medicare drug benefit has given beneficiaries unprecedented access to needed medications, at an affordable cost," said PhRMA Senior Vice President Ken Johnson.

Not only are Medicare beneficiaries saving significant money, so too are American taxpayers. In March 2009, the non-partisan Congressional Budget Office (CBO) released new baseline spending projections that reduced its 10-year forecast for the total cost of the Medicare drug program by $520 billion, or 43 percent, compared with its 2006 estimate for the same 10-year period (FY 2007-2016).

"PhRMA echoes the sentiment shared by President Obama and members of Congress that it is critical that all Americans have access to high-quality and affordable healthcare coverage and will do everything we can to help ensure that a comprehensive healthcare reform bill gets to the White House this year," said PhRMA President and CEO Billy Tauzin.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.

PhRMA Internet Address:

For information on stories of hope and survival, visit:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For more information on public health emergencies, visit

For information on the danger of imported drugs, visit:

SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PhRMA Statement on Healthcare Reform Coalition
2. American Slide Chart/Perrygraf "SlideGuides" and "SpinGuides" Help Drug Companies Satisfy New PhRMA Guidelines
3. PhRMA Honors Gardasil(r) Researchers With Discoverers Award
4. AstraZenecas David Brennan Elected PhRMA Board Chairman
5. PhRMA Statement on Expansion of SCHIP
6. DIA/FDA/PhRMA Drug Safety Conference: Planning the Lifecycle of Safety Evaluation
7. Revised PhRMA Marketing Code Calls for More Educational Materials for Health Care Providers and Staff - Anatstat Health Education Can Help
8. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
9. Johnson & Johnson Announces Commitment To Adopt Revised PhRMA Marketing Code for Responsible Interactions With Healthcare Professionals
10. PhRMA Revised Marketing Code Reinforces Commitment to Responsible Interactions With Healthcare Professionals
11. Richard T. Clark Elected PhRMA Board Chairman
Post Your Comments:
(Date:11/28/2015)... PA (PRWEB) , ... November 28, 2015 , ... Safe ... the creativity of two inventors, one from Lakewood, New Jersey and the other from ... developed the patent-pending PROTECTOR to save the expense of having to replace NuvaRings more ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published November ... meeting in Washington D.C. revolved around the fact that proper dental care, both at-home ... stressed the link between periodontal disease (more commonly referred to as gum disease) and ...
(Date:11/27/2015)... ... November 27, 2015 , ... An ... way to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC ... and dispense prescription medications. In doing so, it could help to prevent potential ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... innovative online platform for mental health and wellness consultation, has collaborated with a ... will bridge the knowledge gap experienced by parents and bring advice from parenting ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... Nov. 27, 2015  Lannett Company, Inc. (NYSE: ... completed the acquisition of Kremers Urban Pharmaceuticals Inc. ... global biopharmaceuticals company UCB S.A. (Euronext: UCB). ... has acquired KU from UCB for total consideration ... including a customary working capital adjustment, a deduction ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... --> --> ... find optimal contrast weighting of MRI for patients with ... a research agreement with SyntheticMR in order to use SyMRI ... is possible to generate multiple contrast images from a single ... left, thus making it possible to both fine tune images ...
Breaking Medicine Technology: